Kapadia told CNBC-TV18, "We have a buy rating on Bilcare. Now Bilcare is in three types of businesses; first is the pharma packaging innovation (PPI) business which contributes about 85% of the revenues."
He further added, "Second is clinical trial supplies, which is about 15% of revenues and they will be shortly launching a third arm of the business called NonClonable Securities Technology. This business is going to revolutionise the entire pharma industry because this will manage the counterfeit drugs in the market and it is expected that using this technology, the counterfeit drugs in the market can substantially get reduced."
The share closed at Rs 510.25, up Rs 1.85, or 0.36% with volumes of 54,308 shares. Its market cap is of Rs 878.04 crore. Currently it is 82.89% above the 52-week low of Rs 279.
